Texas Oncology - Pediatrics
Welcome,         Profile    Billing    Logout  
 9 Trials 
17 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Nemunaitis, John
NCT03495921: A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide

Terminated
3
32
US
Vigil, Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy, FANG vaccine, Irinotecan, Camptosar, Camptothecin-11, CPT-11, Temozolomide, Temodar
Gradalis, Inc.
Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Ewing's Tumor Recurrent, Rare Diseases, Sarcoma, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective Tissue, Sarcoma, Ewing, Neoplasms
01/22
01/22
NCT03073525: A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers

Completed
2
25
US
Vigil, Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy, FANG vaccine, Atezolizumab, TECENTRIQ™, MPDL3280A
Gradalis, Inc., Roche-Genentech
Advanced Gynecological Cancers, Ovarian Cancer, Cervical Cancer, Uterine Cancer
05/19
05/22
FANG Ovarian, NCT01309230: A Trial of FANG™ Vaccine for Participants With Ovarian Cancer

Completed
2
145
US
Vigil™, formerly known as FANG™ vaccine, Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy
Gradalis, Inc.
Ovarian Cancer
02/22
02/22
NCT05503797 / 2022-000627-20: A Study to Assess the Efficacy and Safety of FORE8394 in Participants with Cancer Harboring BRAF Alterations

Recruiting
2
250
Europe, Canada, US, RoW
Plixorafenib, FORE8394, PLX8394, Cobicistat, TYBOST(R)
Fore Biotherapeutics, Fore Biotherapeutics
Cancer Harboring BRAF Alterations
06/25
08/26
VITAL, NCT02346747: A Trial of Vigil for Participants With Ovarian Cancer

Active, not recruiting
2
92
US
Vigil, bi-shRNAfurin and GMCSF Autologous Tumor Cell Immunotherapy, FANG vaccine, Placebo
Gradalis, Inc.
Ovarian Cancer, Ovarian Neoplasms
12/25
12/25
NCT02736565: Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma

Completed
1
7
US
pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex, Lipoplex
Gradalis, Inc.
Ewing's Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Ewing's Tumor Recurrent, Rare Diseases, Sarcoma
08/19
08/20
NCT03556228: Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

Recruiting
1
82
US
VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
VM Oncology, LLC
Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer, Mesothelioma, Thymic Carcinoma, Cervical Cancer, Ovarian Cancer, Bladder Cancer, Esophageal Cancer, Uterine Cancer, Sarcoma, Any Solid Tumors Progressed After a Prior Immunotherapy, Thymoma, Appendiceal Cancer, Olfactory Neuroblastoma
07/26
12/26
NCT03842865: Expanded Access of Vigil in Solid Tumors

Temporarily Not Available
N/A
US
Vigil, Engineered Autologous Tumor Cell Immunotherapy, FANG, IND 14205
Gradalis, Inc.
Solid Tumor, Ewing Sarcoma, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Advanced Gynecological Cancers, Ovarian Cancer, Cervical Cancer, Uterine Cancer
 
 
NCT05236114: GEMINI-NSCLC: NSCLC Biomarker Study

Recruiting
N/A
1200
US
Observation
Tempus AI, AstraZeneca
Non-Small Cell Lung Cancer
06/29
06/29
NCT06207032: TEMPUS ARIES: A Biobank Registry Platform Study in Oncology

Recruiting
N/A
500
US
Tempus AI
Cancer
06/29
06/29
Polaris, NCT06018753: Umbrella Study for Analysis of Data Related to Patients with Cancer

Recruiting
N/A
10000
US
Tempus AI
Cancer
09/28
12/28
Manning, Luisa
NCT03495921: A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide

Terminated
3
32
US
Vigil, Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy, FANG vaccine, Irinotecan, Camptosar, Camptothecin-11, CPT-11, Temozolomide, Temodar
Gradalis, Inc.
Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Ewing's Tumor Recurrent, Rare Diseases, Sarcoma, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective Tissue, Sarcoma, Ewing, Neoplasms
01/22
01/22
NCT03073525: A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers

Completed
2
25
US
Vigil, Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy, FANG vaccine, Atezolizumab, TECENTRIQ™, MPDL3280A
Gradalis, Inc., Roche-Genentech
Advanced Gynecological Cancers, Ovarian Cancer, Cervical Cancer, Uterine Cancer
05/19
05/22
VITAL, NCT02346747: A Trial of Vigil for Participants With Ovarian Cancer

Active, not recruiting
2
92
US
Vigil, bi-shRNAfurin and GMCSF Autologous Tumor Cell Immunotherapy, FANG vaccine, Placebo
Gradalis, Inc.
Ovarian Cancer, Ovarian Neoplasms
12/25
12/25
NCT02736565: Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma

Completed
1
7
US
pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex, Lipoplex
Gradalis, Inc.
Ewing's Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Ewing's Tumor Recurrent, Rare Diseases, Sarcoma
08/19
08/20
NCT03842865: Expanded Access of Vigil in Solid Tumors

Temporarily Not Available
N/A
US
Vigil, Engineered Autologous Tumor Cell Immunotherapy, FANG, IND 14205
Gradalis, Inc.
Solid Tumor, Ewing Sarcoma, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Advanced Gynecological Cancers, Ovarian Cancer, Cervical Cancer, Uterine Cancer
 
 
Ghisoli, Maurizio
LEAP2MONO, NCT05222906 / 2021-005402-10: Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3

Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Venglustat, imiglucerase, Cerezyme®
Sanofi, Sanofi-aventis recherche & développement
Gaucher's Disease Type III
09/25
10/26

Download Options